UK digital healthtech Numan has raised $60 million in fresh funding, following another year of exceptional growth.
Numan is on a mission to help people live happier, healthier, longer lives. It offers personalised, integrated care in one digital platform – including clinical guidance, medication, behavioural health coaching, diagnostics and supplements, to help patients take control of their health. Our focus is on supporting people with stigmatised diseases and conditions, such as obesity and testosterone deficiency, which traditionally are undertreated, mistreated or misunderstood.
The latest financing is an extension of Numan’s Series B round. It comprises a new $30 million equity investment led by Big Pi Ventures, through its new Growth Fund strategy, joined by Endeavor Catalyst as well as existing investors: White Star Capital and Novator Partners.
The fundraise also includes access to $27 million in growth capital from HSBC Innovation Banking, who support the UK’s leading health technology innovators and investors.
Numan saw revenue more than double year-on-year to $90 million by the end of 2024. Building on the profitability first achieved 18 months ago, Numan continues to scale rapidly and is on track to achieve 150% growth in 2025. To date, the company has treated over 650,000 patients across obesity management, men’s health, and diagnostics, while maintaining a market-leading NPS of 68, cementing its position as one of Europe’s fastest-growing and most trusted health platforms.
According to Sokratis Papafloratos, CEO of Numan, the latest funding is a testament to both our commercial performance and belief in our long-term vision for providing personalised, preventative health at scale:
"We started 2025 in a very strong position, one that allowed us to be genuinely choiceful about our next move. Over the past 18 months we’ve seen an explosion in demand – our patients have shown incredible engagement and achieved life-changing outcomes.
This interest fuelled our growth and success in both reaching and maintaining profitability. That’s why we believe now is the time to invest in scaling what works and innovating for the future of healthcare.”
*Nick Kalliagkopoulos, Partner at Big Pi Ventures, said:
“Numan has demonstrated exceptional growth and a clear vision to tackle some of healthcare’s most pressing challenges, from obesity to hormonal health.
We are excited to back a company that combines clinical rigour with technological innovation to deliver better health outcomes. The team’s focus on preventative care, patient engagement, and scalable technology sets Numan apart in the digital health sector.”
Michael White, Head of Life Sciences at HSBC Innovation Banking UK,* added:
“Our team is committed to backing bold innovators, like Numan, equipping them with the tools they need to help them reach their next milestones. We look forward to seeing Numan continue to expand its reach across the UK and beyond.”
Specifically, the funding will enable Numan’s expansion into female health and deepen patient relationships through enhanced screening and preventive care programmes.
It will also go towards scaling the platform’s infrastructure to serve a growing patient base, expanding marketing efforts to reach more people in need, and advancing Numan’s AI-driven capabilities in a careful, clinically responsible manner."
Would you like to write the first comment?
Login to post comments